Advertisement Pharmaceutical Business review - Page 13 of 5252 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
December 4, 2025

FDA approves Eli Lilly’s Jaypirca in relapsed or refractory CLL/SLL

Eli Lilly and Company has received approval from the US Food and Drug Administration (FDA) for the expanded use of Jaypirca (pirtobrutinib) tablets, in 100mg and 50mg doses, to treat adults with relapsed or refractory chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL).

Continue
The trial enrolled 238 patients, randomised 1:1 to receivethe therapy or an investigator-chosen regimen. Credit: Motortion Films/Shutterstock.com.
December 4, 2025

Formosa and Rxilient sign licensing agreement for APP13007

Formosa is a clinical stage biotechnology company focusing on oncology and ophthalmology. Credit: THICHA SATAPITANON/Shutterstock.com.
December 3, 2025

AGC Biologics to expand cell line development with ATUM partnership

The partnership leverages cell engineering expertise to support antibody development for oncology, viral infection treatment, and immune modulation. Credit: Tapati Rinchumrus / Shutterstock.com.

Contracts

January 23, 2025

Kamada to supply immune globulin products in Latin America

KAMRAB must be administered alongside a complete rabies vaccine regimen. Credit: Nappy on Unsplash.

Bavarian Nordic secures $156.8m US vaccine deal

Boehringer Ingelheim receives EC conditional marketing approval for spesolimab

Marinus Pharmaceuticals signs collaboration agreement with Tenacia Biotechnology

Deals

Deals January 20, 2025

Fermion and Simcere to partner on development of pain treatment drug

Pharmaceutical Business Review

WuXi Biologics and Sino Biopharm collaborate on monoclonal antibody discovery

Merck enhances ophthalmology portfolio with EyeBio acquisition

Biocon signs licensing and supply deal for diabetes drug in Brazil

Popular

  1. Citizen Health and UCB collaborate for epilepsy drug development
  2. Solid Biosciences’ SGT-212 gains FDA rare paediatric disease status
  3. Lotus submits NDA for VIZZ in South Korea to treat presbyopia
  4. Eisai seeks PMDA approval for subcutaneous Leqembi in Japan
  5. US FDA approves Lupin’s Armlupeg injection

PRESS RELEASES

Pharmaceutical Business Review
LTS completes acquisition of Renaissance Lakewood, expanding global CDMO capabilities
Gerresheimer at CPHI Frankfurt 2025
Gerresheimer at CPHI Frankfurt 2025
Pharmaceutical Business Review
LTS and Nualtis Announce Strategic Cooperation to Expand Global Manufacturing Capabilities, Accelerate Market Expansion, and Ensure Customer Success
LTS Wins Funding from BARDA’s Patch Forward Prize Competition for Two artnerships
LTS Wins Funding from BARDA’s Patch Forward Prize Competition for Two artnerships
Gerresheimer Delivers Solid Results in the Financial Year 2024 Despite Market Headwinds
Gerresheimer Delivers Solid Results in the Financial Year 2024 Despite Market Headwinds

Suppliers

Whitepapers

Pharmaceutical Business Review
EVERIC® Pure – The Safe Option Right from the Start
Saving Through Partnership and Innovation
Saving Through Partnership and Innovation
Case Study: Exploring Machine Translation in a Global Pharmacovigilance Programme
Case Study: Exploring Machine Translation in a Global Pharmacovigilance Programme